文献速递神经肿瘤小儿神经外科与脑积水

高剂量化疗联合避免颅脊髓照射策略治疗幼儿期WNT型髓母细胞瘤

High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood.
PubMed 文献 · J Neurooncol · 2026-01-19

该国际协作队列纳入5例WNT型髓母细胞瘤患儿,中位诊断年龄7.0岁(范围2.7–7.5),均接受高剂量化疗及自体干细胞移植,未行辅助放疗。所有患者诊断后生存超过四年,评估患儿神经认知能力处于低平均至平均范围。结论认为单用高剂量化疗在该队列中生存极佳,幼儿期WNT型髓母细胞瘤分子诊断不应作为排除高剂量化疗巩固策略的标准。

要点

  • 幼儿期WNT型髓母细胞瘤极罕见,高剂量化疗联合避免放疗策略生存极佳。
  • 5例患儿均未接受辅助放疗,全部生存超过诊断后四年。
  • 评估患儿神经认知能力处于低平均至平均范围。

核心结论

  • 在该队列中,单用高剂量化疗治疗幼儿期WNT型髓母细胞瘤的生存极佳。
  • 幼儿期WNT型髓母细胞瘤的分子诊断不应被视为排除依赖高剂量化疗巩固的婴儿脑肿瘤策略的标准。

研究设计与样本

  • 通过国际协作组装队列,纳入接受高剂量化疗并避免颅脊髓照射的幼儿WNT型髓母细胞瘤患儿,描述其生存及神经认知与耳毒性特征。

主要发现

  • 5例患者中位诊断年龄7.0岁(范围2.7–7.5),均接受高剂量化疗及自体干细胞移植,无一接受辅助放疗。
  • 所有患者诊断后生存超过四年。
  • 评估患者的神经认知能力报告处于低平均至平均范围。

临床怎么用

  • 幼儿期WNT型髓母细胞瘤的分子诊断不应作为排除高剂量化疗巩固策略的排除标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant chemotherapy and craniospinal irradiation led to excellent survival in older children (≥ 3 years) with WNT medulloblastoma, allowing for ongoing careful treatment de-escalation. However, treatment with standard dose chemotherapy alone or in combination with involved field radiotherapy to the tumor bed only had high rates of distant treatment failure. In younger children, WNT medulloblastomas are extremely rare and the survival following high-dose chemotherapy (HDC) and radiation-sparing strategies has not been reported. PATIENTS AND METHODS: Through international collaboration, we assembled a cohort of young children with WNT medulloblastoma treated with HDC and craniospinal irradiation avoidance to describe their survival and neurocognitive and ototoxicity profile. RESULTS: Five patients, diagnosed at median age of 7.0 years (range 2.7–7.5) underwent HDC and autologous stem cell transplantation. None of them received adjuvant radiotherapy. All patients were alive beyond four years from diagnosis. Evaluated patients had neurocognitive abilities reported within low average to average range. CONCLUSION: In this cohort, the survival of young children with WNT MB treated with HDC alone was excellent. The rare possibility of a molecular diagnosis of WNT MB in early childhood should not be viewed as an exclusion criterion to enroll on infant brain tumor strategies relying on HDC consolidation. CLINICAL TRIAL NUMBER: Not applicable.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nobre L, Ramaswamy V, Coleman C, et al. High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood. J Neurooncol. 2026. PMID: 41553441. doi:10.1007/s11060-026-05425-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。